Celldex Therapeutics, Inc.
CLDX
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6B
$39.68
▲ +0.79%
P/E
-9.10
Mkt Cap
$2.6B
52-Wk Range
$22.10–$45.14
52-Week Range
$22.10 - $45.14
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 69.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bispecific antibody technology platform combining multiple immune mechanisms
- Strategic partnerships with Amgen, Yale University, and University of Southampton providing research validation and resources
- Experienced management team with deep expertise in antibody engineering and immunotherapy development
- Diverse pipeline addressing multiple cancer types and inflammatory conditions with differentiated mechanisms of action
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical advancement of CDX-527 bispecific antibody combining CD27 costimulation with PD-L1 blockade
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+38.9% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CLDX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.94 vs -$1.06 consensus (+11.3% surprise). Revenue of $22.0K vs $734.9K expected (-97.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.3%
Revenue trend · last 8Q
—
-72%
+346%
-71%
-100%
-94%
-98%
-97%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.2M
$1.2M
$695.0K
$730.0K
$0
$75.0K
$15.0K
$22.0K
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
-334104.5%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Aug 7, 2026
vs Industry
How CLDX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related